Erratum. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2016;39:2042—2050
Tonneijck, Lennart, Smits, Mark M., Muskiet, Marcel H.A., Hoekstra, Trynke, Kramer, Mark H.H., Danser, A.H. Jan, ter Wee, Piet M., Diamant, Michaela, Joles, Jaap A., van Raalte, Daniel H.Journal:
Diabetes Care
DOI:
10.2337/dc19-er03
Date:
January, 2019
File:
PDF, 431 KB
2019
File converter
More search results
More benefits 
